CC reports Q2 results today carrying a contradictory signal: short sellers have been cutting positions even as the stock remains nearly 6% below where it was a month ago.
Short interest has fallen meaningfully over the past two weeks. Positions dropped from roughly 12.8 million shares in mid-July to 11.3 million today — a decline of around 11% — bringing the short interest to 7.6% of the free float. That is still a substantial bearish position for a chemicals name, but the direction of travel is clearly toward covering rather than building. Borrow conditions add little urgency on either side: cost to borrow is a negligible 0.47%, and availability is extremely loose at over 1,100% of short interest, meaning there are roughly twelve shares available to borrow for every one already lent out. The lending market offers no obstacle to new short sellers, but also no squeeze pressure for existing ones.
Options positioning reinforces the idea that traders are leaning bullish into the print. The put/call ratio is running at 0.18, well below its 20-day average of 0.19 and close to its 52-week low of 0.14. That skew toward calls — rather than the defensive put-buying that typically appears ahead of uncertain prints — aligns with the stock's recent recovery. CC climbed nearly 5% on Monday and added another 5% over the week, partially clawing back a sharper 5.7% monthly decline.
The analyst community is broadly constructive but selectively cautious. Most recent moves — from UBS, RBC, and Truist — were target raises ahead of last quarter's results, and the mean target of roughly $24.70 implies 38% upside from current levels. The most recent action, however, cut against that direction: Mizuho trimmed its target from $30 to $25 in early July while holding its Outperform rating, a sign the firm sees improving fundamentals but a less generous path to recovery than it did before. JP Morgan and Morgan Stanley sit at Neutral, anchoring the consensus below the bulls. The bull case centres on pricing power in the Flex portal and distribution channels, improving TiO2 margins, and the "Pathway to Thrive" cost programme targeting over $250 million in incremental savings through 2027. Bears point to regulatory headwinds compressing HFC and HFO demand, new TiO2 capacity threatening pricing, and a housing and automotive end-market backdrop that remains soft.
The earnings history sharpens the stakes. The last comparable print — Q1 2026 — delivered a brutal one-day drop of nearly 20%, followed by a partial five-day recovery that still left shareholders down almost 10%. That reaction came despite a recent note flagging stronger-than-expected Q2 results and raised full-year guidance, which, if accurate, would represent a sharp reversal in fortunes. The print today will test whether that guidance uplift is enough to convince the Street that the May collapse was a bottom, or whether execution risk in TiO2 and fluoroproducts remains too high to justify a re-rating.
See the live data behind this article on ORTEX.
Open CC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
